PhRMA and BIO mobilize against a wave of anti-China biotech bills in Congress as lawmakers move to curb US dealmaking with China.
Biopharma industry lobby groups working to keep the pipeline open for plentiful, lower-cost drugs coming from China have awakened to the fact that they face …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
As China biotech crackdown calls reverberate in Washington, the pushback gets louder, too
House bill aims to crack down on China biotech deals
The next tech war? Why biotech may become a new US-China battleground
US lawmakers reveal policy to curb collaboration with Chinese biotech - Pharmaceutical Technology
美国两党议员推动立法，限制对华生物技术投资
Two federal lawmakers have introduced a bill seeking to apply the review requi | Two federal lawmakers have introduced a bill…
As large biopharma companies have increasingly turned to China for novel biotech innovation, political calls in the U.S. to block…
China's ascent is forcing U.S. biotech companies and investors to pick a side: Is it an ally or an existential threat?
A key US House Republican urges Treasury to restrict US investment in China biotech, spotlighting Bristol Myers Squibb's Hengrui…
A proposal to add biotechnology to the COINS Act follows two big deals involving Pfizer and Bristol Myers, and comes amid U.S.…
China’s biotech industry is rapidly moving up the value chain, prompting fears in the US and calls for tighter controls.
